The Monekypox (Mpox) diagnosis market caters to the diagnosis of monkeypox infection. Monkeypox is a rare viral zoonotic infection caused by the monkeypox virus. Since the outbreak of monkeypox in non-endemic countries in 2022, the demand for Mpox diagnosis tests has increased substantially. Monkeypox diagnosis helps in early detection of the disease and can aid in management and control of the spread of infection. The major diagnostic tests for Mpox include polymerase chain reaction (PCR) tests, antigen and antibody tests, and histopathology. PCR tests allows for rapid and sensitive detection of the virus, while antigen and antibody blood tests determine active or past infection. Histopathology enables diagnosis by detecting virus in skin lesions through electron microscopy.

Global monkeypox (Mpox) diagnosis market is estimated to be valued at USD 1.97 Bn in 2024 and is expected to reach USD 2.62 Bn by 2031, exhibiting a compound annual growth rate (CAGR) of 4.2% from 2024 to 2031.

Key Takeaways

Key players operating in the Mpox diagnosis market are Aegis Sciences Corporation, Laboratory Corporation of America Holdings, Quest Diagnostics Incorporated, Sonic Healthcare Limited, QIAGEN, Mayo Clinic Laboratories, Chembio Diagnostics, Inc., Sonora Quest Laboratories, Thermo Fisher Scientific, BD (Becton, Dickinson and Company), CerTest Biotech, GenMark Diagnostics, Inc., Roche Diagnostics, Abbott Laboratories, Hologic, Inc., Siemens Healthineers, PerkinElmer, Inc., Bio-Rad Laboratories, Inc., Agilent Technologies, Inc., and Meridian Bioscience, Inc. The key players are focused on launching new diagnostic tests as well as expanding their production capacities to meet the rising demand post the monkeypox outbreak.

The key opportunities in the Monkeypox (Mpox) Diagnosis Market Demand include development of rapid point-of-care diagnostic tests to enable diagnosis at early stages. Present tests in use take days to provide results, delaying treatment. Development of rapid tests with turnaround time of an hour can boost case identification. Geographical expansion into monkeypox endemic regions in Africa presents another opportunity for players.

Global expansion is a key focus area for major players in the Mpox diagnosis market. Most players have a strong presence across North America and Europe. However, focus is now shifting to emerging markets in Asia Pacific and Latin America owing to rising penetration of healthcare facilities and increasing infection rates. New product launches catering to requirements of developing nations will further aid global expansion plans over the coming years.

Market Drivers

The major driver for the Mpox diagnosis market is the rising prevalence of monkeypox cases globally. Since May 2022, when the first cases were reported outside Africa, the virus has spread to over 80 countries with thousands of confirmed infections. As more individuals get tested, need for confirmatory diagnosis through PCR, antigen or antibody tests is surging tremendously. Increased public awareness about symptoms is also contributing to the driver demand for tests.

Market Restraints

High prices of PCR and antigen diagnostic tests limit their widespread adoption, especially in developing regions. PCR tests can cost over $100 per sample in certain locations. This makes early diagnosis difficult for people in low income countries or without health insurance. Limited availability of diagnostic tests and lack of healthcare infrastructure in remote areas also acts as a restraint on market growth. Strict regulations for new diagnostic approvals further delays market entry of innovative products.

Segment Analysis
The Monkeypox (Mpox) Diagnosis market is dominated by the PCR assays and kits sub segment. PCR assays are the gold standard for the diagnosis of Monkeypox virus infection as they provide rapid detection of viral DNA with high sensitivity and specificity. PCR assays can detect the virus early in infection before rash onset. They are able to amplify and detect even a small number of viral DNA copies. This makes PCR the most sensitive and accurate diagnostic test for Mpox currently available.

Global Analysis
North America is the fastest growing and dominating region in the global Monkeypox (Mpox) Diagnosis market. This is because countries in North America like the United States witnessed the highest number of Mpox cases globally in 2022. Also, highly developed healthcare infrastructure and early widespread availability of diagnostic tests in the region facilitated rapid large-scale testing.

Additionally, high healthcare spending per capita in countries like the US and Canada has enabled wider adoption of advanced diagnostics. Meanwhile, Europe is another major regional market supported by outbreaks in countries such as the UK, Spain and Germany. The availability of reliable testing and effective contact tracing has helped control further spread.

About Author:

Alice Mutum is a seasoned senior content editor at Coherent Market Insights, leveraging extensive expertise gained from her previous role as a content writer. With seven years in content development, Alice masterfully employs SEO best practices and cutting-edge digital marketing strategies to craft high-ranking, impactful content. As an editor, she meticulously ensures flawless grammar and punctuation, precise data accuracy, and perfect alignment with audience needs in every research report. Alice's dedication to excellence and her strategic approach to content make her an invaluable asset in the world of market insights.

(LinkedIn: www.linkedin.com/in/alice-mutum-3b247b137 )